Chris Lau
All posts from Chris Lau
Chris Lau in Value Stocks,

Deep Dive on Analyst Actions for Valeant Pharma (VRX)

Analysts are getting louder on their bearish calls for Valeant stock. Unable to accept the B+L and Salix organic revenue growth, three analysts issued hold or sell ratings.


David Amsellem of Piper Jaffray, a one-star analyst (per Tipranks) has a -2.1% return and a 42% success rate over two years. Net ranking: Ranked #3,809 out of 4,628 Analysts on TipRanks(#8,959 out of 10,691 overall experts)

His VRX PT? $14.00.

Selvaraju of H..C. Wainwright has a ‘hold’ rating and PT $17.00. He has a 30% success rate and a -11.5% return over two years.

Irina Koffler of Mizuho Securities has a 4-star rating and calls VRX stock a SELL with a PT $8.00. Koffler is right just 47% of the time and has a 10.5% return over 2-years. She has 3,700 followers on tipranks.

For comparison purposes, my success rate is 59% on an average return of 15.7%. 49th /6,000 overall.

Related: ENDP is on a downtrend. TEVA is breaking down to new lows. AGN is holding up. MYL is following the generic drug suppliers lower on the markets.